secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001171843-25-004186
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst sells European ORLADEYO rights to Neopharmed Gentili for up to $264M
-----------------------------------------------------------------------------

- Neopharmed Gentili pays $250M upfront, up to $14M milestones; closing expected by early October 2025.
- Proceeds to retire all $249M remaining term debt, eliminating ~$70M future interest payments.
- BioCryst now expects ~$700M cash and no term debt by end 2027, a $400M increase from prior guidance.
- Sale includes European team; BioCryst saves at least $50M in annual operating expenses.
- European ORLADEYO revenues still count toward global royalty tiers for OMERS and >$550M cap.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/0001171843-25-004186-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184325004186/f8k_062725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004186

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer